Amgen (AMGN) Getting Somewhat Positive Press Coverage, Report Finds
News coverage about Amgen (NASDAQ:AMGN) has trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned news stories about the medical research company an impact score of 46.2039378082959 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Amgen’s (AMGN) Hold Rating Reaffirmed at Royal Bank of Canada (americanbankingnews.com)
- JPMorgan Chase & Co. Raises Amgen (AMGN) Price Target to $189.00 (americanbankingnews.com)
- Hot Tickers: Enterprise Products Partners LP (EPD), Amgen Inc. (AMGN) – Market Movers (financialqz.com)
- “Stock’s Report of the Day — Amgen Inc. (AMGN) – usstockjournal (usstockjournal.com)
- Short Sellers Raise the Stakes in Major Biotechs – 24/7 Wall St. (247wallst.com)
Several equities analysts have recently commented on the stock. BidaskClub upgraded shares of Amgen from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Argus raised shares of Amgen from a “hold” rating to a “buy” rating and lifted their price objective for the company from $192.33 to $220.00 in a research note on Tuesday, January 23rd. JPMorgan Chase & Co. lifted their price objective on shares of Amgen from $184.00 to $189.00 and gave the company a “neutral” rating in a research note on Wednesday, January 24th. Royal Bank of Canada reissued a “hold” rating and set a $189.00 target price on shares of Amgen in a research report on Wednesday, January 24th. Finally, Oppenheimer set a $205.00 target price on shares of Amgen and gave the stock a “buy” rating in a research report on Friday, January 5th. Fifteen research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Amgen has an average rating of “Hold” and a consensus price target of $191.28.
Amgen declared that its Board of Directors has initiated a share buyback program on Wednesday, October 25th that authorizes the company to buyback $5.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s management believes its shares are undervalued.
The business also recently announced a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. This represents a $5.28 dividend on an annualized basis and a dividend yield of 2.69%. This is a positive change from Amgen’s previous quarterly dividend of $1.15. The ex-dividend date of this dividend is Wednesday, February 14th. Amgen’s dividend payout ratio is presently 41.63%.
In other news, Director Carbonnel Francois De sold 4,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $173.61, for a total transaction of $694,440.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $171.58, for a total transaction of $261,659.50. Following the completion of the transaction, the executive vice president now owns 57,631 shares in the company, valued at $9,888,326.98. The disclosure for this sale can be found here. Insiders have sold 8,575 shares of company stock worth $1,508,836 over the last quarter. 0.19% of the stock is owned by company insiders.
COPYRIGHT VIOLATION WARNING: “Amgen (AMGN) Getting Somewhat Positive Press Coverage, Report Finds” was first reported by Marea Informative and is owned by of Marea Informative. If you are accessing this article on another domain, it was stolen and reposted in violation of international copyright & trademark law. The legal version of this article can be accessed at https://www.mareainformativa.com/2018/01/29/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-amgen-amgn-share-price-updated-updated-updated.html.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.